Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Blood (2024) 144 (Supplement 1): 731.

https://doi.org/10.1182/blood-2024-198614

Published: 2024

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Blood (2024) 144 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2024-201251

Published: 2024

Journal Articles

Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Blood (2024) 144 (Supplement 1): 4946.

https://doi.org/10.1182/blood-2024-212055

Published: 2024

Journal Articles

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

Blood (2023) 142 (Supplement 1): 3530.

https://doi.org/10.1182/blood-2023-180581

Published: 2023

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 2235.

https://doi.org/10.1182/blood-2023-184383

Published: 2023

Journal Articles

Early Autologous Hematopoietic Stem Cells (AHSC) Boost (HCB) to Overcome Immune Effector Cell-Associated Hematotoxicity (ICAHT) after CAR T-Cell Therapy for Lymphoma: A Single Center Experience

Safia Yousfi, Blandine Guffroy, Celestine Simand, Karin Bilger, Elise Toussaint, Mathieu Baldacini, Luc Matthieu Fornecker, Bruno Lioure

Blood (2023) 142 (Supplement 1): 6902.

https://doi.org/10.1182/blood-2023-182401

Published: 2023

Journal Articles

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

Blood (2021) 138 (Supplement 1): 262.

https://doi.org/10.1182/blood-2021-147709

Published: 2021

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Risk Factors for Severe Form of COVID-19 after Allogeneic Hematopoietic Stem Cell Transplantation: A SFGM-TC Multicentre Cohort Study

Alienor Xhaard, MD, Constance Xhaard, Maud D'Aveni, MD, Hélène Salvator, MD PhD, Marie-Laure Chabi-Charvillat, MD, Tereza Coman, MD PhD, Yves Beguin, MD PhD, Yves Chalandon, MD, Xavier Poire, MD, Michael Loschi, MD PhD, Catherine Paillard, MD PhD, Bénédicte Bruno, MD, Patrice Ceballos, MD PhD, Jean-Hugues Dalle, MD PhD, Karin Bilger, MD, Jacques-Olivier Bay, MD PhD, Marie Robin, MD PhD, Stephanie N'guyen-Quoc, MD PhD, Marie Thérèse Rubio, MD PhD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-138411

Published: 2020

Journal Articles

CMV Status Predicts Survival in Refractory/Relapsed Myeloid Patients after a Clofarabine-Based Sequential Regimen: A Retrospective Study on Behalf of the SFGM-TC

Amandine Le Bourgeois, PhD, Myriam Labopin, MD PhD, Felipe Suarez, MD PhD, Regis Peffault De Latour, MD PhD, Didier Blaise, Sylvain Chantepie, Stephanie Nguyen-Quoc, Natacha Maillard, MD, Reza Tabrizi, MD, Ibrahim Yakoub-Agha, Anne Huynh, MD, Tony Marchand, Karin Bilger, Patrice Ceballos, MD, Amandine Charbonnier, Pascal Turlure, MD, Mohamad Mohty, MD PhD, Patrice Chevallier, MD

Blood (2017) 130 (Supplement 1): 3217.

https://doi.org/10.1182/blood.V130.Suppl_1.3217.3217

Published: 2017

Journal Articles

Clofarabine/Busulfan-Based Reduced Intensity Conditioning Regimens Provides Very Good Survivals in Patients Allografted in Remission for Acute Myeloid Leukemia: A Retrospective Study on Behalf of the SFGM-TC

Amandine Le Bourgeois, PhD, Myriam Labopin, MD PhD, Sebastien Maury, MD PhD, Regis Peffault De Latour, MD PhD, Jean-Henri Bourhis, Patrice Ceballos, MD, Sylvie François, Karin Bilger, Didier Blaise, Thierry Guillaume, MD PhD, Mohamad Mohty, MD PhD, Patrice Chevallier, MD

Blood (2017) 130 (Supplement 1): 1952.

https://doi.org/10.1182/blood.V130.Suppl_1.1952.1952

Published: 2017

Journal Articles

RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Final Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO - SFGM-TC French intergroup)

Blood (2017) 130 (Supplement 1): 4599.

https://doi.org/10.1182/blood.V130.Suppl_1.4599.4599

Published: 2017

Journal Articles

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD

Gérard Socié, Stéphane Vigouroux, Ibrahim Yakoub-Agha, Jacques-Olivier Bay, Sabine Fürst, Karin Bilger, Felipe Suarez, Mauricette Michallet, Dominique Bron, Philippe Gard, Zakaria Medeghri, Philippe Lehert, Chinglin Lai, Tim Corn, Jean-Paul Vernant

Blood (2017) 129 (5): 643–649.

https://doi.org/10.1182/blood-2016-09-738625

Published: 2017

Includes: Supplemental data

Journal Articles

Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study

Blood (2016) 128 (22): 2777.

https://doi.org/10.1182/blood.V128.22.2777.2777

Published: 2016

Journal Articles

Impact of NK Cell Reconstitution and Recipient HLA-C Typing on Clinical Outcome after Reduced Intensity Cord Blood Transplant: Results of a Prospective Phase II Multicentric Trial on Behalf of Societe Francaise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord

Blood (2015) 126 (23): 4393.

https://doi.org/10.1182/blood.V126.23.4393.4393

Published: 2015

Journal Articles

Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

Xavier Cahu, MD, Patrice Chevallier, MD, PhD, Aline Clavert, MD, Felipe Suarez, MD, PhD, Mauricette Michallet, MD, Nathalie Fegueux, MD, Stephane Vigouroux, MD, Didier Blaise, Gérard Socié, MD, PhD, Clara Mariette, Karin Bilger, MD, Ibrahim Yakoub-Agha, MD, PhD, Regis Peffault de Latour, Mohamad Mohty, MD, PhD

Blood (2013) 122 (21): 3373.

https://doi.org/10.1182/blood.V122.21.3373.3373

Published: 2013

Journal Articles

Reconstitution Of NK Cells After Reduced Intensity Conditioned Unrelated Cord Blood Transplantation In Patients With Acute Myeloid Leukemia: Analysis Of a Prospective Phase II Multicentric Trial On Behalf Of Societe Française De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord

Blood (2013) 122 (21): 4606.

https://doi.org/10.1182/blood.V122.21.4606.4606

Published: 2013

Journal Articles

Phase II Prospective Multicentre Study Testing The Efficacy and Safety Of a Clofarabine (Clo), I.v. Busulfan (Bu) and Antithymocyte Globulins (ATG)-Based Reduced-Intensity Conditioning Regimen (RIC) Before Allogeneic Stem Cell Transplantation (allo-SCT) For High-Risk Myelodysplastic Syndrome Or Acute Leukemia: The Cloric Trial

Patrice Chevallier, MD, PHD, Myriam Labopin, MD, Gérard Socié, MD, PhD, Stephane Vigouroux, MD, Sabine Furst, MD, Marie Y. Detrait, MD, Bruno Lioure, MD, Thierry Guillaume, MD, Jacques Delaunay, MD, Regis Peffault de la Tour, MD, PhD, Noel Milpied, MD, PhD, Didier Blaise, Mauricette Michallet, MD, PhD, Karin Bilger, MD, Philippe Moreau, MD, Mohamad Mohty, MD, PhD

Blood (2013) 122 (21): 413.

https://doi.org/10.1182/blood.V122.21.413.413

Published: 2013

Journal Articles

Conditioning Intensity In Middle Aged Patients With AML In CR1. No Advantage For Myeloablative Regimens Irrespective Of The Risk Group. An Observational Analysis By The Acute Leukemia Working Party Of The EBMT

Blood (2013) 122 (21): 542.

https://doi.org/10.1182/blood.V122.21.542.542

Published: 2013

NARROW

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Early Autologous Hematopoietic Stem Cells (AHSC) Boost (HCB) to Overcome Immune Effector Cell-Associated Hematotoxicity (ICAHT) after CAR T-Cell Therapy for Lymphoma: A Single Center Experience

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Risk Factors for Severe Form of COVID-19 after Allogeneic Hematopoietic Stem Cell Transplantation: A SFGM-TC Multicentre Cohort Study

CMV Status Predicts Survival in Refractory/Relapsed Myeloid Patients after a Clofarabine-Based Sequential Regimen: A Retrospective Study on Behalf of the SFGM-TC

Clofarabine/Busulfan-Based Reduced Intensity Conditioning Regimens Provides Very Good Survivals in Patients Allografted in Remission for Acute Myeloid Leukemia: A Retrospective Study on Behalf of the SFGM-TC

RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Final Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO - SFGM-TC French intergroup)

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD

Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study

Impact of NK Cell Reconstitution and Recipient HLA-C Typing on Clinical Outcome after Reduced Intensity Cord Blood Transplant: Results of a Prospective Phase II Multicentric Trial on Behalf of Societe Francaise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord

Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

Reconstitution Of NK Cells After Reduced Intensity Conditioned Unrelated Cord Blood Transplantation In Patients With Acute Myeloid Leukemia: Analysis Of a Prospective Phase II Multicentric Trial On Behalf Of Societe Française De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord

Conditioning Intensity In Middle Aged Patients With AML In CR1. No Advantage For Myeloablative Regimens Irrespective Of The Risk Group. An Observational Analysis By The Acute Leukemia Working Party Of The EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only